Product Description: Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Joseph Chao, et al. Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. 2020 ASCO Annual Meeting I.
CAS Number: 2413453-53-7
Molecular Weight: N/A
Compound Purity: 98.44
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: CD3